Levodopa/Carbidopa/Entacapone Orion 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IG/1580 
A.7 - Administrative change - Deletion of 
12/01/2023 
manufacturing sites 
Annex II and 
PL 
PSUSA/547/2
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
02110 
carbidopa / entacapone / levodopa 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
WS/2202/G 
This was an application for a group of variations 
31/03/2022 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.z - Quality change - Active substance - Other 
variation 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
IG/1495 
B.III.1.a.2 - Submission of a new/updated or 
14/03/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
WS/2175 
This was an application for a variation following a 
27/01/2022 
16/12/2022 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
Page 2/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS/2105/G 
This was an application for a group of variations 
25/11/2021 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
WS/2124/G 
This was an application for a group of variations 
16/09/2021 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
Page 3/14 
 
 
 
 
 
 
 
 
 
 
 
 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IG/1408/G 
This was an application for a group of variations. 
17/06/2021 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IG/1303 
B.II.b.2.c.1 - Change to importer, batch release 
25/11/2020 
01/07/2022 
SmPC, Annex 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
II, Labelling 
and PL 
WS/1735/G 
This was an application for a group of variations 
12/03/2020 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
Page 4/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.d.1.b.3 - Stability of AS - Change in the storage 
conditions - Change in storage conditions of the AS 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
WS/1667/G 
This was an application for a group of variations 
05/12/2019 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
PSUSA/547/2
Periodic Safety Update EU Single assessment - 
29/05/2019 
08/08/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
01810 
carbidopa / entacapone / levodopa 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/547/201810. 
IG/1060 
A.7 - Administrative change - Deletion of 
28/02/2019 
n/a 
manufacturing sites 
Page 5/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/0965/G 
This was an application for a group of variations. 
23/10/2018 
n/a 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
WS/1327 
This was an application for a variation following a 
08/02/2018 
08/08/2019 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
IG/0867 
B.II.b.3.a - Change in the manufacturing process of 
20/11/2017 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IG/0858/G 
This was an application for a group of variations. 
30/10/2017 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
Page 6/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IG/0807 
A.5.b - Administrative change - Change in the name 
10/08/2017 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
R/0019 
Renewal of the marketing authorisation. 
01/04/2016 
26/05/2016 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Levodopa/Cabidopa/Entacapone Orion in the approved 
indication remains favourable and therefore recommended 
the renewal of the marketing authorisation with unlimited 
validity. 
PSUSA/547/2
Periodic Safety Update EU Single assessment - 
13/05/2016 
n/a 
PRAC Recommendation - maintenance 
01510 
carbidopa / entacapone / levodopa 
IG/0631/G 
This was an application for a group of variations. 
04/12/2015 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
Page 7/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0017 
Minor change in labelling or package leaflet not 
29/09/2015 
PL 
connected with the SPC (Art. 61.3 Notification) 
N/0016 
Minor change in labelling or package leaflet not 
02/06/2015 
22/01/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
IG/0546 
C.I.8.a - Introduction of or changes to a summary of 
27/04/2015 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 8/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS/0665 
This was an application for a variation following a 
22/01/2015 
22/01/2016 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
To update the Product Information as follows: 
- to include ADR statement 
- to update the PI to QRD template version 9 
- to include an explanation to the PL of the pictogram 
which is currently only displayed on the carton (all 
products except Comtan) 
- to correct the local contact information for Malta in 
Stalevo PL 
- to correct the local contact information for Latvia in 
all PLs except for Comtan and Entacapone Orion 
- to correct the local contact information for 
Germany in Comtess and 
Levodopa/Carbidopa/Entacapone Orion 
- for Comtan only: to add 'Magnesium stearate' to 
the list of excipients for the film-coating in the SmPC 
and PL. Tablet core and Film-coating both contain 
magnesium stearate 
- to correct linguistic amendments in Annexes 
- to amend a mistake in the Annex A (only for 
Comtan). 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
WS/0651 
This was an application for a variation following a 
18/12/2014 
n/a 
To include an additional analytical method for the active 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
substance carbidopa. 
Page 9/14 
 
 
 
 
 
 
 
 
 
 
To include an additional analytical method for the 
active substance carbidopa. 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
N/0012 
Minor change in labelling or package leaflet not 
30/06/2014 
22/01/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
IG/0433/G 
This was an application for a group of variations. 
08/05/2014 
n/a 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0010/G 
This was an application for a group of variations. 
17/03/2014 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
Page 10/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.3 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IG/0415/G 
This was an application for a group of variations. 
13/03/2014 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0008 
Minor change in labelling or package leaflet not 
14/08/2013 
22/01/2016 
PL 
connected with the SPC (Art. 61.3 Notification) 
X/0003 
Annex I_2.(c) Change or addition of a new 
25/04/2013 
27/06/2013 
SmPC, 
strength/potency 
Labelling and 
PL 
IA/0007 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
13/05/2013 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
Page 11/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/0302/G 
This was an application for a group of variations. 
13/05/2013 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
B.III.1.a.2 - Submission of a new or updated Ph. Eur. 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - Updated certificate from an already 
approved manufacturer 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
Page 12/14 
 
 
 
 
 
 
 
 
 
 
WS/0331 
This was an application for a variation following a 
13/12/2012 
14/01/2013 
SmPC, Annex 
Based on a recent review of the available post-marketing 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
II, Labelling 
data in relation to the risk of development of impulse 
and PL 
control disorders when using medicinal products containing 
Update of SmPC sections 4.4 and 4.8 in order to 
update the safety information by implementing class 
labelling for the risk of impulse control disorders. 
C.I.3.z - Implementation of change(s) requested 
following the assessment of an USR, class labelling, a 
PSUR, RMP, FUM/SO, data submitted under A 45/46, 
or amendments to reflect a Core SPC - Other 
variation 
IG/0229 
B.III.1.a.3 - Submission of a new or updated Ph. Eur. 
09/11/2012 
n/a 
Certificate of Suitability to the relevant Ph. Eur. 
Monograph - New certificate from a new 
manufacturer (replacement or addition) 
WS/0199 
This was an application for a variation following a 
19/01/2012 
19/01/2012 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.III.2.a.1 - Change of specification('s) of a former 
non Pharmacopoeial substance to comply with the 
Ph. Eur. or with a national pharmacopoeia of a 
Member State - AS 
levodopa, dopamine agonists and/or catechol-O-
methyltransferase (COMT) inhibitors, the CHMP/PhVWP 
requested a class labelling to update and harmonise the 
product information of all products concerned. In response 
to this request, the product information was updated to 
reflect behavioural symptoms related to impulse control 
disorders including compulsive spending or buying, binge 
eating and compulsive eating. It was clarified that this 
adverse reaction can occur irrespective of the indication 
and at normal doses. Furthermore, regular monitoring of 
patients and a careful review of treatment, if symptoms 
occur, is recommended. The Package Leaflet was updated 
in accordance and advice for the patient’s family and carers 
was provided. 
Page 13/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IG/0110 
C.I.9.i - Changes to an existing pharmacovigilance 
04/10/2011 
n/a 
system as described in the DDPS - Change(s) to a 
DDPS following the assessment of the same DDPS in 
relation to another medicinal product of the same 
MAH 
Page 14/14 
 
 
 
 
 
 
 
 
 
